PBS Update: Semaglutide (Wegovy) Recommended for Cardiovascular Risk in Obesity
The PBAC has recommended the PBS listing of semaglutide 2.4 mg for patients with established cardiovascular disease and severe obesity. This article outlines the specific eligibility criteria, including BMI thresholds and ethnicity adjustments, and examines the administrative implications for Australian general practice.
PBS Update: Semaglutide (Wegovy) Recommended for Cardiovascular Risk in Obesity Read More »